Contrasting Immunovant (NASDAQ:IMVT) and enGene (NASDAQ:ENGN)

enGene (NASDAQ:ENGN) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Insider & Institutional Ownership

64.2% of enGene shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 5.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

enGene has a beta of -0.76, suggesting that its stock price is 176% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for enGene and Immunovant, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	9	1	3.10
Immunovant	0	0	11	0	3.00

enGene presently has a consensus price target of $30.38, suggesting a potential upside of 252.79%. Immunovant has a consensus price target of $48.10, suggesting a potential upside of 67.42%. Given enGene’s stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Immunovant.

Profitability

This table compares enGene and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-66.38%	-56.00%
Immunovant	N/A	-56.40%	-52.03%

Valuation & Earnings

This table compares enGene and Immunovant”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$99.92 million	N/A	N/A
Immunovant	N/A	N/A	-$259.34 million	($2.22)	-12.94

Summary

enGene beats Immunovant on 6 of the 10 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.